Načítám výsledky…
Cell and gene therapy (CGT) products are complex biologic medicines that often require specialized, more resource-intensive patient care, close monitoring,...
Capital Gains Tax (CGT) is generally payable when chargeable assets are sold for more than they cost and the cumulative total of gains and losses is above...
DHCS, CMS and the CGT sickle cell disease medication manufacturers will work together to determine that these benchmark outcomes have been reached and report.
The CGT Access Model aims to support beneficiaries and address health equity... The CGT Access Model will operate for up to approximately 11 years...
The CGT Access Model aims to reduce healthcare costs by facilitating outcomes-based agreements between manufacturers and states. The Cell and...
CGT is a tax on any increase in the value of an asset when it is transferred by sale or gift to a third party. It also applies to a sale or transfer at an...
Holistic CGT roadmap w/ prioritization of areas in most need of harmonization with recommendations for revisions to existing ICH guidelines and/or possibly...
The field of cell and gene therapy (CGT) is rapidly developing, with the number of therapies in development greatly increasing over the last five years.
The CGT Access Model, administered by the Centers for Medicare & Medicaid Services. (CMS), is a new federal initiative that tests whether CMS-led outcomes-based...